ARIAD
Pharmaceuticals, Inc. ARIA today announced that the U.S.
Food and Drug Administration (FDA) has accepted for filing the New Drug
Application (NDA) for accelerated review of ARIAD's investigational
BCR-ABL inhibitor, ponatinib,
in patients with resistant or intolerant chronic myeloid leukemia (CML)
or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+
ALL). The FDA also has granted ARIAD's request for Priority Review,
which is given to investigational medicines that have the potential for
providing significant improvement in the treatment, prevention, or
diagnosis of a disease. The FDA has established an action date of March
27, 2013 under the Prescription Drug User Fee Act (PDUFA).
About Ponatinib
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in